Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes

References

• Albain KS, Unger JM, Crowley JJ, Coltman CA, Hershman DL. 2009. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology group. J Natl Cancer Inst. 101:984–992.
   PubMed Web of Science ®Google Scholar
• Andersson S, D'Arcy P, Larsson O, Sehat B. 2009. Focal adhesion kinase activates and stabilizes IGF1 receptor. Biochem Biophys Res Commun. 387:36–41.
   PubMed Web of Science ®Google Scholar
• Avruch A. 1998. Insulin signal transduction through protein kinase cascades. Mol Cell Biochem. 182:31–48.
   PubMed Web of Science ®Google Scholar
• Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. 1995. Mammary cancer in transgenic mice expressing insulin-like growth factor II. Br J Cancer. 72:1189–1193.
   PubMed Web of Science ®Google Scholar
• Belfiore A. 2007. The role of insulin receptor isoforms and hybrid insulin/IGF1 receptors in human cancer. Curr Pharm Design. 13:671–686.
   PubMed Web of Science ®Google Scholar
• Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. 2009. Insulin receptors isoforms and insulin receptor/IGF receptor hybrids in physiology and disease. Endocr Rev. 30 6: 586–623.
   PubMed Web of Science ®Google Scholar
• Buchanan CM, Phillips AR, Cooper GJ. 2001. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet β-cells and enhances insulin secretion. Biochem J. 360:431–439.
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. 2006. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 295:2492–2502.
   PubMed Web of Science ®Google Scholar
• Christofori G, Naik P, Hanahan D. 1994. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 369:414–418.
   PubMed Web of Science ®Google Scholar
• D'Ambrosio C, Keller SR, Morrione A, Lienhard GE, Baserga R, Surmacz E. 1995. Transforming potential of the insulin receptor substrate 1 signaling. Cell Growth Differ. 6:557–562.
   PubMedGoogle Scholar
• Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrin M, Gros L, Bosch F. 2000. Transgenic mice overexpressing insulin-like growth factor II in β cells develop type 2 diabetes. J Clin Invest. 105:731–740.
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. 1999. Insulin receptor isoform A, a newly recognized, high affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 19:3278–3288.
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Malaguarnera R, Mandarino A, Messina RL, Sciacca L, Belfiore A, Vigneri R. 2007. Role of c-Abl in directing metabolic versus mitogenic effects in insulin receptor signaling. J Biol Chem. 282 36: 26077–26088.
   PubMed Web of Science ®Google Scholar
• Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, Curnen MM, Soler-Vila H, Beeghly A, Duan F, Owens P. 2004. African American/white differences in breast carcinoma: p53 alterations and other tumor characteristics. Cancer. 101:1293–1301.
   PubMed Web of Science ®Google Scholar
• Kalla-Singh S, Tan QT, Brito C, De León M, De León D. Differential insulin like growth factor-II (IGF-II) expression: A potential role for breast cancer survival disparity. Growth Horm IGF Res. 2010a; 20:162–170.
   PubMed Web of Science ®Google Scholar
• Kalla-Singh S, Tan QT, Brito C, De León M, De León D. Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women. Growth Horm IGF Res. 2010b; 20:245–254.
   PubMed Web of Science ®Google Scholar
• Kalla-Singh S, Moretta D, Almaguel F, Wall NR, DeLeon M, DeLeon D. 2008. Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors. 25 6: 363–372.
   Web of Science ®Google Scholar
• Kao AW, Waters SB, Okada S, Pessin JE. 1997. Insulin stimulates the phosphorylation of the 66- and 52- kilodalton Shc isoforms by distinct pathways. Endocrinology. 138:2474–2480.
   PubMed Web of Science ®Google Scholar
• Louvi A, Accili D, Efstratiadis A. 1997. Growth promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol. 189:33–48.
   PubMed Web of Science ®Google Scholar
• Moller DE, Yokota A, Caro JF, Flier JS. 1989. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol. 3:1263–1269.
   PubMed Web of Science ®Google Scholar
• Moorehead RA, Hojilla CV, De Belle I, Wood GA, Fata JE, Adamson ED, Watson KL, Edwards DR, Khokha R. 2003. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. J Biol Chem. 278 50: 50422–50427.
   PubMed Web of Science ®Google Scholar
• Morrione A, Valentinis B, Xu SQ, Yumet G, Louvi A, Efstratiadis A, Baserga R. 1997. IGF-II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci. 94:3777–3782.
   PubMed Web of Science ®Google Scholar
• Myers MG, White MF. 1996. Insulin signal transduction and the IRS proteins. Annu Rev Pharmacol Toxicol. 36:615–658.
   PubMed Web of Science ®Google Scholar
• Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C. 2003. Breast cancer genetics in African Americans. Cancer. 97:236–245.
   PubMedGoogle Scholar
• Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A. 1999. IGF1R overexpression in breast cancers leads to insulin/IGF1 hybrid receptor overexpression: Evidence for a second mechanism of IGF-signaling. Clin Cancer Res. 5:1935–1944.
   PubMed Web of Science ®Google Scholar
• Pravtcheva DD, Wise TL. 1998. Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool. 281 1: 43–57.
   PubMedGoogle Scholar
• Pravtcheva DD, Wise TL. 2003. Transgene instability in mice injected with an in vitro methylated Igf2 gene. Mutat Res. 529:35–50.
   PubMed Web of Science ®Google Scholar
• Rose DP, Haffner SM, Baillargeon J. 2007. Adiposity, the metabolic syndrome, and breast cancer in African-American and White American women. Endocr Rev. 28:763–777.
   PubMed Web of Science ®Google Scholar
• Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. 2006. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 17:567–604.
   Web of Science ®Google Scholar
• Samani AA, Yakar S, Leroith D, Brodt P. 2007. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev. 28 1: 20–47.
   PubMed Web of Science ®Google Scholar
• Schlaepfer DD, Hanks SK, Hunter T, van der Greer P. 1994. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature. 372:786–791.
   PubMed Web of Science ®Google Scholar
• Sciacca L, Constantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R, Belfiore A. 1999. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene. 18:2471–2479.
   PubMed Web of Science ®Google Scholar
• Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. 2003. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology. 144:2650–2658.
   PubMed Web of Science ®Google Scholar
• Singer CF, Mogg M, Koestler W, Pacher M, Marton E, Kubista E, Schreiber M. 2004. Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: Free IGF-II is correlated with breast cancer size. Clin Cancer Res. 10:4003–4009.
   PubMed Web of Science ®Google Scholar
• Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL. 1996. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer. Cancer Res. 56:2781–2788.
   PubMed Web of Science ®Google Scholar
• Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. 2005. Diabetes mellitus and breast cancer. Lancet Oncol. 6:103–111.
   PubMed Web of Science ®Google Scholar
• Zhang L, Kashanchi F, Zhan Q, Brady JN, Fornace AJ, Seth P, Helman LJ. 1996. Regulation of IGF-II P3 promoter by p53: A potential mechanism for tumorigenesis. Cancer Res. 65 6: 1367–1373.
   Google Scholar
• Zhang LJ, Zhan QM, Zhan SL, Kashanchi F, Fornace AJ, Seth P, Helman LJ. 1998. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol. 17 1: 1–7.
   PubMed Web of Science ®Google Scholar